Innoviva EBITDA 2010-2024 | INVA

Innoviva ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Innoviva Annual EBITDA
(Millions of US $)
2023 $152
2022 $495
2021 $398
2020 $343
2019 $265
2018 $259
2017 $202
2016 $126
2015 $49
2014 $-18
2013 $-21
2012 $-18
2011 $-102
2010 $-72
2009 $-76
Innoviva Quarterly EBITDA
(Millions of US $)
2024-03-31 $36
2023-12-31 $29
2023-09-30 $48
2023-06-30 $37
2023-03-31 $38
2022-12-31 $30
2022-09-30 $297
2022-06-30 $87
2022-03-31 $82
2021-12-31 $110
2021-09-30 $100
2021-06-30 $102
2021-03-31 $85
2020-12-31 $90
2020-09-30 $90
2020-06-30 $81
2020-03-31 $81
2019-12-31 $79
2019-09-30 $65
2019-06-30 $64
2019-03-31 $57
2018-12-31 $82
2018-09-30 $63
2018-06-30 $68
2018-03-31 $46
2017-12-31 $72
2017-09-30 $45
2017-06-30 $52
2017-03-31 $33
2016-12-31 $42
2016-09-30 $32
2016-06-30 $30
2016-03-31 $22
2015-12-31 $21
2015-09-30 $13
2015-06-30 $10
2015-03-31 $5
2014-12-31 $5
2014-09-30 $-5
2014-06-30 $-6
2014-03-31 $-11
2013-12-31 $22
2013-09-30 $-6
2013-06-30 $-5
2013-03-31 $-31
2012-12-31 $-28
2012-09-30 $-31
2012-06-30 $-34
2012-03-31 $88
2011-12-31 $-33
2011-09-30 $-27
2011-06-30 $-22
2011-03-31 $-20
2010-12-31 $-16
2010-09-30 $-18
2010-06-30 $-18
2010-03-31 $-20
2009-12-31 $-19
2009-09-30 $-20
2009-06-30 $-20
2009-03-31 $-17
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.009B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $841.118B 121.57
Novo Nordisk (NVO) Denmark $629.915B 48.40
Johnson & Johnson (JNJ) United States $351.255B 13.95
Merck (MRK) United States $322.933B 58.76
AbbVie (ABBV) United States $299.632B 15.48
AstraZeneca (AZN) United Kingdom $245.898B 21.38
Novartis AG (NVS) Switzerland $214.477B 15.21
Pfizer (PFE) United States $152.885B 19.00
Sanofi (SNY) $119.633B 11.29